title: Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
abstract: Pityriasis rubra pilaris has no single effective therapy and there are some cases resistant to multiple treatments. Psoriasis has clinical and therapeutic response overlaps with pityriasis rubra pilaris and there are several therapies common to both, such as retinoids, methotrexate, cyclosporine A, phototherapy, and most recently infliximab. We report a case of a 10-year-old boy with pityriasis rubra pilaris unresponsive to topical corticosteroids, salicylic acid, pimecrolimus, calcitriol, calcipotriol, ultraviolet B targeted phototherapy, isotretinoin, systemic PUVA, acitretin, and etanercept. He was treated with efalizumab 1 mg/kg weekly and a successful outcome was obtained with a 50% improvement after the first dose. The patient remains in remission after 9 months of treatment.
authors: Department of Dermatology, University Hospital U.A.N.L. Dr. Jose Eleuterio González, Monterrey, Nuevo León, Mexico.
authors: Minerva
authors: M
authors: Gómez
authors: Maira E Herz
authors: ME
authors: Ruelas
authors: Oliverio
authors: O
authors: Welsh
authors: Horacio Decanini
authors: HD
authors: Arcaute
authors: Jorge
authors: J
authors: Ocampo-Candiani
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D006801:Humans; D008297:Male; D010789:Phototherapy; D010916:Pityriasis Rubra Pilaris / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab